An evaluation of the clinical evidence on the role of inflammation and oxidative stress in smoking-mediated cardiovascular disease

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 127-139

  Csordas, Adam ^a   Wick, Georg ^a   Laufer, Günther ^a   Bernhard, David ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Atherosclerosis; Clinical study; CRP; Heavy metals; ROS

Indexed keywords

7BETA HYDROXYCHOLESTEROL; ALPHA TOCOPHEROL; ASCORBIC ACID; C REACTIVE PROTEIN; CERIVASTATIN; DOPA; HEAVY METAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; ISOPROSTANE DERIVATIVE; MEVINOLIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYSTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY OBSTRUCTION; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LOW DRUG DOSE; MONOTHERAPY; NITRATION; OBESITY; OXIDATIVE STRESS; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; URINARY EXCRETION;

NICOTIANA TABACUM;

EID: 41049089280     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s480     Document Type: Review

References (88)

1. [Anonymous], 1982. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA, 248(12), 1465-77.
2. [Anonymous], 1993. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur. Heart J., 14(1):8-17.
3. Albert, M.A., Danielson, E., Rifai, N. and Ridker, P.M. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA,286(1):64-70.
4. Awad, J.A., Morrow, J.D., Takahashi, K. and Roberts, L.J. 1993. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J. Biol. Chem., 268(6):4161-9.
5. Beckman, J.A., Liao, J.K., Hurley, S., Garrett, L.A., Chui, D., Mitra, D. and Creager, M.A. 2004. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ. Res., 95(2):217-23.
6. Bermudez, E.A., Rifai, N., Buring, J.E., Manson, J.E. and Ridker, P.M. 2002. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol., 89(9):1117-9.
7. Bernhard, D., Csordas, A., Henderson, B., Rossmann A., Kind, M. and Wick, G. 2005. Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB. J., 19(9):1096-107.
8. Bernhard, D., Pfister, G., Huck, C.W., Kind, M., Salvenmoser, W., Bonn, G.K. and Wick, G. 2003. Disruption of vascular endothelial homeostasis by tobacco smoke: impact on atherosclerosis. FASEB. J., 17(15):2302-4.
9. Bernhard, D., Rossmann, A., Henderson, B., Kind, M., Seubert, A. and Wick, G. 2006. Increaped serum cadmium and strontium levels in young smokers: effects on arterial endothelial cell gene transcription. Arterioscler Thromb. Vasc. Biol., 26(4):833-8.
10. Bernhard, D. and Wang, X.L. 2007. Smoking, oxidative stress and cardio-vascular diseases - do anti-oxidative therapies fail? Curr. Med. Chem., 14(16):1703-12.
11. Blankenberg, S., Barbaux, S. and Tiret, L. 2003. Adhesion molecules and atherosclerosis. Atherosclerosis, 170(2):191-203.
12. Blankenberg, S., McQueen, M.J., Smieja, M., Pogue, J., Balion, C., Lonn, E., Rupprecht, H.J., Bickel, C.. Tiret, L., Cambien, F., Gerstein, H., Munzel, T. and Yusuf, S. 2006. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 114(3):201-8.
13. Blann, A.D., Steele, C. and McCollum, C.N. 1997. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb. Res., 85(5):433-8.
14. Bothig, S. 1989. WHO MONICA Project: objectives and design. Int. J. Epidemiol., 18(3 Suppl 1):S29-S37.
15. Braunwald, E. 1997. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med., 337(19):1360-9.
16. bu-Hayyeh, S., Sian, M., Jones, K.G., Manuel, A. and Powell, J.T. 2001. Cadmium accumulation in aortas of smokers. Arterioscler Thromb. Vasc. Biol., 21(5):863-7.
17. Csordas, A., Wick, G. and Bernhard, D. 2006. Hydrogen peroxide-mediated necrosis induction in HUVECs is associated with an atypical pattern of caspase-3 cleavage. Exp. Cell. Res., 312(10):1753-64.
18. Danesk J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B. and Gudnason, V. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med., 350(14):1387-97.
19. Das, I. 1985. Raised C-reactive protein levels in serum from smokers. Clin. Chim. Acta., 153(1):9-13.
20. Davi, G., Ciabattoni, G., Consoli, A., Mezzetti, A., Falco, A., Santarone, S., Pennese, E., Vitacolonna, E., Bucciarelli, T., Costantini, F, Capani, F. and Patrono, C. 1999. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation, 99(2)224-9.
21. Davies, M.J., Fu, S., Wang, H. and Dean, R.T. 1999. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic. Biol. Med., 27(11-12):1151-63.
22. Dean, R.T., Fu, S., Stocker, R. and Davies, M.J. 1997. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J., 324 (Pt 1):1-18.
23. Delanty, N., Reilly, M.P., Pratico, D., Lawson, J.A., McCarthy, J.F., Wood, A.E., Ohnishi, S.T., Fitzgerald, D.J. and FitzGerald, G.A. 1997. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation, 95(11):2492-9.
24. Dyer, R.G., Stewart, M.W, Mitcheson, J., George, K., Alberti, M.M. and Laker, M.F. 1997. 7-ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease. Clin. Chim. Acta., 260(1):1-13.
25. Fickl, H., Van, A., V, Richards, G.A., Van der Westhuyzen, D.R., Davies, N., Van der, W.R., Van der Merwe, C.A. and Anderson, R. 1996. Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers. Atherosclerosis, 124(1):75-81.
26. Folsom, A.R., Chambless, L.E., Ballantyne, C.M., Coresh, J., Heiss, G., Wu, K.K., Boerwinkle, E., Mosley TH Jr, Sorlie, R, Diao, G. and Sharrett, A.R. 2006. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch. Intern. Med., 166(13):1368-73.
27. Fu, S., Davies, M.J., Stocker, R. and DearL R.T. 1998. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem. J., 333 ( Pt 3):519-25.
28. Haverkate, F., Thompson, S.G., Pyke, S.D., Gallimore, J.R. and Pepys, M.B. 1997. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Corcerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet, 349(9050):462-6.
29. Hulthe, J., Wikstrand, J. and Fagerberg, B. 2001. Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR.) study. Clin. Sci. (Lond), 100(4):371-8.
30. Hwang, S.J., Ballantyne, C.M., Sharrett, A.R., Smith, L.C., Davis, C.E., Gotto, A.M. Jr. and Boerwinkle, E. 1997. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 96(12):4219-25.
31. Jousilahti, P., Vartiainen, E., Tuomilehto, J. and Puska, P. 1996. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet, 348(9027):567-72.
32. Kalra, J., Chaudhary, A.K. and Prasad, K. 1991. Increased production of oxygen free radicals in cigarette smokers. Int. J. Exp. Pathol., 72(1):1-7.
33. Kaur, H, and Halliwell, B. 1994. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett, 350(1):9-12.
34. Knoflach, M., Kiechl, S., Kind, M., Said, M., Sief, R., Gisinger, M., van der, Z.R., Gaston, H., Jarosch, E., Willeit, J. and Wick, G. 2003. Cardiovascular risk factors and atherosclerosis in young males: ARMY. study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation, 108(9):1064-9.
35. Koenig, W., Sund, M., Frohlich, M., Fischer, H.G., Lowel, H., Doring, A., Hutchinson, W.L. and Pepys, M.B. 1999. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 99(2):237-42.
36. Koskela, R.S., Mutanen, P., Sorsa, J.A. and Klockars, M. 2005. Respiratory disease and cardiovascular morbidity. Occup. Environ. Med., 62(9):650-5.
37. Kuller, L.H., Tracy, R.P., Shaten, J. and Meilahn, E.N. 1996. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study Multiple Risk Factor Intervention Trial. Am. J Epidemiol., 144(6):537-47.
38. Lawson, J.A., Rokach, J. and FitzGerald, G.A. 1999. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem., 274(35):24441-4.
39. Leonarduzzi, G., Chiarpotto, E., Biasi, F. and Poli, G. 2005.4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res., 49(11):1044-9.
40. Leonarduzzi, G., Sottero, B. and Poli, G. 2002. Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J. Nutr. Biochem., 13(12):700-10.
41. Libby, P., Ridker, P.M. and Maseri, A. 2002. Inflammation and atherosclerosis. Circulation, 105(9):1135-43.
42. Liu, C.S., Lii, C.K., Ou, C.C., Tsai, C.H., Wei, Y.H. and Chen, H.W. 2000. Autoantibody against oxidized low-density lipoproteins may be enhanced by cigarette smoking. Chem. Biol. Interact, 127(2):125-37.
43. Mazzone, A., Cusa, C., Mazzucchelli, I., Vezzoli, M., Ottini, E., Ghio, S., Tossini, G., Pacifici, R. and Zuccaro, P. 2001. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. Clin. Chem. Lab. Med., 39(9):822-6.
44. Meisinger, C., Baumert, J, Khuseyinova, N., Loewel, H. and Koenig, W. 2005. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation, 112(5):651-7.
45. Mendall, M.A., Patel, P., Ballam, L., Strachan, D. and Northfield, T.C. 1996. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ., 312(7038):1061-5.
46. Mol, M.J., de Rijke, Y.B., Demacker, P.N. and Stalenhoet, A.F. 1997. Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis, 129(2):169-76.
47. Mora, S. and Ridker, P.M. 2006. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER.) - can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol., 97(2A):33A-41A.
48. Morrow, J.D., Frei, B., Longmire, A.W., Gaziano, J.M., Lynch, S.M., Shyr, Y., Strauss, W.E., Oates, J.A. and Roberts, L.J. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med., 332(18):1198-203.
49. Morrow, J.D., Hill, K.E., Burk, R.F., Nammour, T.M., Badr, K.F. and Roberts, L.J. 1990. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A., 87(23):9383-7.
50. Mosca, L. 2002. C-reactive protein - to screen or not to screen? N. Engl. J. Med., 347(20):1615-7.
51. Mulvihill, N.T., Boccalatte, M. and Foley, J.B. 2002. Inflammatory markers as predictors of clinical outcome in acute coronary syndromes. Minerva Cardioangiol., 50(6):653-9.
52. Patrono, C. and FitzGerald, G.A. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb. Vasc. Biol., 17(11):2309-15.
53. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., III Criqui, M., Fadl, Y.Y., Fortmann, S.Y., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C. Jr., Taubert, K.,Tracy, R.P. and Vinicor, F. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3):499-511.
54. Petruzzelli, S., Puntoni, R., Mimotti, P., Pulera, N., Baliva, F., Fornai, E. and Giuntini, C. 1997. Plasma 3-nitrotyrosine in cigarette smokers. Am. J. Respir. Crit. Care Med., 156(6):1902-7.
55. Pignatelli, B.,Li C.Q.,Boffetta, P., Chen, Q., Ahrens, W., Nyberg, F., Mukeria, A., Bruske-Hohlfeld, I., Fortes, C., Constantinescu, V., Ischiropoulos, H. and Ohshima, H. 2001. Niltrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res., 61(2):778-84.
56. Pitz, H., Oguogho, A., Chehne, F., Lupattelli, G., Palumbo, B. and Sinzinger, H. 2000. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb. Res., 99(3):209-21.
57. Reilly, M., Delanty, N., Lawson, J.A. and FitzGenald, G.A. 1996. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation, 94(1):19-25.
58. Ridker, P.M., Buring, J.E. and Rifai, N. 2001a. Soluble P-selectin and the risk of future cardiovascular events. Circulation, 103(4):491-5.
59. Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P. and Hennekens, C.H. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med., 336(14):973-9.
60. Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P. and Hennekens, C.H. 1998a. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 97(5):425-8.
61. Ridker, P.M., Glynn, R.J. and Hennekens, C.H. 1998b. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation, 97(20):2007-11.
62. Ridker, P.M., Hennekens, C.H., Buring, J.E. and Rifai, N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 342(12):836-43.
63. Ridker, P.M., Hennekens, C.H., Roitman-Johnson, B., Stampfer, M.J. and Allen, J. 1998c. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet, 351(9096):88-92.
64. Ridker, P.M., Rifai, N., Clearfield, M., Downs, J.R., Weis, S.E., Miles, J.S. and Gotto, A.M. Jr. 2001b. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med., 344(26):1959-65.
65. Ridker, P.M., Rifai, N. and Lowenthal, S.P. 2001c. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation, 103(9):1191-3.
66. Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F. and Braunwald, E. 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100(3):230-5.
67. Ridker. P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman. S., Flaker, G.C. and Braunwald, E. 1998d. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 98(9):839-44.
68. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. and Cook, N.R. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 347(20): 1557-65.
69. Roberts, L.J. and Morrow, J.D. 1994. Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann. N. Y. Acad. Sci., 744:237-42.
70. Rohde, L.E., Hennekens, C.H. and Ridker, P.M. 1999. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am. J. Cardiol, 84(9):1018-22.
71. Ross, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 340(2):115-26.
72. Salonen, J.T., Nyyssonen, K., Korpela, H., Tuomilehto, J., Seppanen, R. and Salonen, R. 1992. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation, 86(3):803-11.
73. Salonen, J.T., Nyyssonen, K., Salonen, R., Porkkala-Sarataho, E., Tuomainen, T.P., Diczfalusy, U. and Bjorkhem, I. 1997. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation, 95(4):840-5.
74. Schmieder, A., Schwaiger, S., Csordas, A., Backovic, A., Messner, B., Wick, G., Stuppner, H. and Bernhard, D. 2006. Isogentisin-A novel compound for the prevent ion of smoking-caused endothelial injury. Atherosclerosis,
75. Shimada, K., Mokuno, H., Matsunaga, E., Miyazaki, T., Sumiyoshi, K., Miyauchi, K. and Daida, H. 2004. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis, 174(2):343-7.
76. Shishehbor, M.H., Aviles, R.J., Brennan, M.L., Fu, X., Goormastic, M., Pearce, G.L., Gokce, N., Keaney, JF Jr, Penn, M.S., Sprecher, D.L., Vita, J.A. and Hazen, S.L. 2003. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 289(13):1675-80.
77. Stadtman, E.R. and Oliver, C.N. 1991. Metal-catalyzed oxidation of proteins. Physiological consequewnces. J. Biol. Chem., 266(4):2065-8.
78. Stadtman, E.R., Starke-Reed, P.E., Oliver, C.N., Carney, J.M. and Floyd, R.A. 1992. Protein modification in aging. E.S. 62:64-72.
79. Tracy, R.P., Psaty, B.M., Macy, E., Bovill, E.G., Cushman, M., Cornell, E.S. and Kuller, L.H. 1997. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb. Vasc. Biol., 17(10).2167-76.
80. Tuomainen, T.P., Diczfalusy, U., Kaikkonen, J., Nyyssonen, K. and Salonen, J.T. 2003. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic. Biol. Med., 35(8):922-8.
81. Wallenfeldt, K., Fagerberg, B., Wikstrand, J. and Hulthe, J. 2004. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in-clinically healthy men, J. Intern Med., 256(5):413-20.
82. Wang, T.J., Gona, P., Larson, M.G., Tofter, G.H., Levy, D., Newton-Cheb, C., Jacques, P.F., Rifai, N., Selhub, J., Robins, S.J., Benjamin, E.J., D'Agostino, R.B. and Vasan, R. S. 2006. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med., 355(25):2631-9.
83. Wilson, P.W., Nam, B.H., Pencina, M., D'Agostino, R.B. Sr., Benjamin, E.J. and O'Donnell, C.J. 2005. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med., 165(21):2473-8.
84. Wu, T., Willett, W.C., Rifai, N., Shai, I., Manson, J.E. and Rimm, E.B 2006. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart. disease among U.S men and women? J. Am. Coll Cardiol.. 48(5):973-9.
85. Yamaguchi, Y., Haginaka, J., Morimoto, S., Fujioka, Y and Kunitomo, M. 2005. Facilitated nitration and oxidation of LDL in cigarette smokers. Eur. J. Clin. Invest., 35(3):186-93.
86. Yamaguchi, Y., Kagota, S., Haginaka, J. and Kunitomo, M. 2002. Participation of peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette smoke. FEBS Lett, 512(1-3):218-22.
87. Yasunobu, Y., Hayashi, K., Shingu, T., Yamagata, T., Kajiyama, G. and Kambe, M. 2001. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprofein and oxysterols. Atherosclerosis, 155(2):445-53.
88. Zieden, B., Kaminskas, A., Kristenson, M., Kucinskiene, Z., Vessby, B., Olsson, A.G. and Diczfalusy, U. 1999. Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb. Vasc. Biol., 19(4):967-71.